Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.

Conditions Studied

Interventions

  • BIOLOGICAL mRNA-1030
  • BIOLOGICAL mRNA-1020
  • BIOLOGICAL mRNA-1010
  • BIOLOGICAL Active Comparator

Study Locations (15)

Florida

  • Alliance for MultiSpecialty Research — Coral Gables
  • Health Awareness, Inc. — Jupiter

North Carolina

  • Lucas Research — Morehead City
  • Trial Management Associates, LLC — Wilmington

Utah

  • Olympus Family Medicine — Salt Lake City
  • South Ogden Family Medicine — South Ogden

Arizona

  • Foothills Research Center — Phoenix

Georgia

  • IACT Health — Columbus

Iowa

  • Meridian Clinical Research — Sioux City

Kansas

  • Heartland Research Associates, LLC — Wichita

Missouri

  • Sundance Clinical Research, LLC — St Louis

Trial Details

FieldValue
Enrollment Target 572 participants
Start Date 2022-04-06
Est. Completion 2022-11-22
Phase Phase 1

Sponsor

ModernaTX

67 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05333289

The ClinicalTrials.gov registry entry for NCT05333289 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 67 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Seasonal Influenza appearing as the primary indexed condition, and to 4 interventions — of which mRNA-1030 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05333289 reports 15 study locations spanning 12 distinct geographic areas — top geographies include Florida, North Carolina, Utah. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05333289 about?

NCT05333289 is a clinical study titled "A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults". The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.

What is the current status of trial NCT05333289?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 572 participants. The study started on 2022-04-06. Estimated completion is 2022-11-22.

What conditions does trial NCT05333289 study?

This clinical trial studies the following conditions: Seasonal Influenza. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05333289?

The interventions under investigation include: mRNA-1030 (BIOLOGICAL), mRNA-1020 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), Active Comparator (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05333289?

This trial is sponsored by ModernaTX, which has 67 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05333289 being conducted?

This trial has 15 study locations across Arizona, Florida, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial